Central angiotensin I increases fetal AVP neuron activity and pressor responses. Am J Physiol Endocrinol Metab 298: E1274 -E1282, 2010. First published April 6, 2010; doi:10.1152/ajpendo.00060.2010.-Angiotensin (Ang) II plays a critical role in cardiovascular homeostasis and neuroendocrine regulation. Little is known about whether central angiotensin-converting enzyme (ACE) is functional in the fetal brain. We investigated cardiovascular and neuroendocrinological responses to intracerebroventricular (icv) application of Ang I in the chronically prepared near-term ovine fetus in utero and examined the action sites marked by c-fos expression in the fetal hypothalamus. ACE mRNA was detected in the specific central areas. Intracerebroventricular Ang I significantly increased fetal blood pressure and c-fos expression in the supraoptic nuclei (SON) and the paraventricular nuclei (PVN) in the hypothalamus, accompanied by an increase of fetal plasma arginine vasopressin (AVP). Double labeling demonstrated that AVP neurons in the fetal SON and PVN were expressing c-fos. Captopril, an inhibitor of ACE, significantly suppressed fetal pressor responses and plasma AVP. Double labeling experiments showed colocalization of AT1 receptor (AT1R) and c-fos expression in both SON and PVN following icv Ang I. The results indicate that central endogenous ACE has been functional at least at the last third of gestation and the endogenous brain renin-angiotensin systemmediated pressor responses and AVP release via AT1Rs by acting at the sites consistent with the cardiovascular network in the hypothalamus. arginine vasopressin; vasopressin; brain development INCREASING EVIDENCE HAS SUGGESTED that an overactivated reninangiotensin system (RAS) (14, 25) contributes to hypertension programmed during fetal life. Low-protein diet during pregnancy elevated blood pressure (BP) in adult offspring (15) associated with increased pulmonary and plasma angiotensinconverting enzyme (ACE) (14), and ACE inhibitors prevented an increase in BP (26). Recent progress has demonstrated that exogenous Ang II reliably induced pressor responses and arginine vasopressin (AVP) release in the fetus (27, 35, 36 ). An abnormal development of the fetal RAS may be linked to diseases in both prenatal and postnatal life. However, little is known about whether central ACE is functional in the fetal brain. To increase understanding of the functional development of the fetal brain, RAS is important to both prenatal and postnatal life.
INCREASING EVIDENCE HAS SUGGESTED that an overactivated reninangiotensin system (RAS) (14, 25) contributes to hypertension programmed during fetal life. Low-protein diet during pregnancy elevated blood pressure (BP) in adult offspring (15) associated with increased pulmonary and plasma angiotensinconverting enzyme (ACE) (14) , and ACE inhibitors prevented an increase in BP (26) . Recent progress has demonstrated that exogenous Ang II reliably induced pressor responses and arginine vasopressin (AVP) release in the fetus (27, 35, 36 ). An abnormal development of the fetal RAS may be linked to diseases in both prenatal and postnatal life. However, little is known about whether central ACE is functional in the fetal brain. To increase understanding of the functional development of the fetal brain, RAS is important to both prenatal and postnatal life.
The brain has its own independent intrinsic RAS. All components of the RAS, such as angiotensinogen, renin, ACE, and angiotensin (Ang) II, have been demonstrated in the brain (10, 18, 23) . ACE (EC 3.4.15.1, dipeptidyl carboxypeptidase I, kininase II), is a zinc metallopeptidase that converts Ang I into Ang II by cleaving the dipeptide, histidine-leucine, from the COOH terminus of Ang I. ACE is a key enzyme in the RAS for production of Ang II, which is critical to physiological and pathophysiological actions. In mature animals, administration of either Ang II or its precursors into the brain produces pressor and dipsogenic responses and causes release of adrenocorticotropic hormone, aldosterone, and AVP (1, 9, 31) . Our previous studies have shown that central application of Ang II can also elicit pressor and neuroendocrine responses in the ovine fetus (27, 35, 36) , as evidenced by the fact that the neurons in the putative cardiovascular network, the paraventricular nuclei (PVN), and the supraoptic nuclei (SON) in the hypothalamus were activated with c-fos expression (35, 36) . Furthermore, the brain AT 1 receptor (AT 1 R) plays an important role in Ang II-mediated fetal cardiovascular and neuroendocrine regulation (12, 27) . Notably, all of these data in fetal studies were based on exogenous Ang II. Whether an endogenous local RAS, in particular, key enzymes such as ACE in the brain, has functionally developed before birth is unclear, although ACE already exists in the developing brain (2, 4, 16, 20, 24, 32) . Notably, presence of chemicals in the fetal brain may not mean those chemicals can function exactly as that in the matured brain if routes or pathways for their functions have not been well established or developed during development periods. Therefore, the present study determined the fetal brain local ACE in the control of cardiovascular and neuroendocrine systems in utero and determined neuropharmacological effects in the fetal hypothalamus following administration of central Ang I at near term.
MATERIALS AND METHODS
Animals and surgical preparation. All protocols and ethical issues in the use of animals in this study were approved by the Soochow University Animal Care Committee, and experiments were conducted in accordance with the National Research Council's Guide for the Care and Use of Laboratory Animals. Time-dated pregnant ewes (gestational day 125 Ϯ 5, term ϳ145 days) were used. Animals (ϳ50 kg Hu sheep) were housed indoors in individual steel cages (125 ϫ 88 ϫ 135 cm) and acclimated to a 12:12-h light-dark cycle. Both food and water were provided ad libitum.
Anesthesia was induced by an intramuscular injection of ketamine hydrochloride (20 mg/kg; Hengrui Medicine, Jiangsu, China) and atropine sulfate (50 g/kg; Linrui Pharmaceutical, Zhengzhou, China) and was maintained by maternal endotracheal ventilation with 1 l/min oxygen and 3% isoflurane. The uterus was exposed by a midline abdominal incision, and a small hysterotomy was performed to provide access to a fetal hindlimb and head. Polyethylene catheters were placed in the maternal and fetal femoral vein and artery and threaded to the inferior vena cava and abdominal aorta, respectively. An intracranial cannulae was placed in the fetal lateral ventricle and held in place with dental cement. The coordinates were anterior-posterior: ϩ0.1 cm in front of the bregma; medial-lateral: 0.8 cm from the middle line; and ventral: 1.8 cm below the dura. Patency of the catheter at insertion was assessed by free flow of cerebrospinal fluid via gravity drainage. The placement of cannulae was verified with histological analysis after the animal was euthanized. The uterine incisions were closed in layers. Catheters were filled with heparinzed saline (80 heparin/ml iu in 0.9% NaCl), and all catheters were passed through a subcutaneous tunnel and exteriorized through a small incision on the ewe's flank. After surgery, pregnant ewes were returned to individual pens and allowed free access to water and food. Antibiotics were administered intravenously daily to the ewe (70 mg of gentamicin and 1 g of oxacillin; North China Pharmaceutical) and to the fetus (5 mg of gentamicin and 30 mg of oxacillin) for 3 days postsurgery. Four days were allowed for postoperative recovery.
Cardiovascular experiments. All experiments were performed on unanesthetized ewes standing in the cages and on fetuses in utero. Fetal body weight was estimated according to the following formula: fetal weight (kg) ϭ 0.0961 ϫ gestation age (days) Ϫ 9.228 (19) . Studies began with a baseline period (Ϫ60 to 0 min) followed by an experimental period (0 -120 min) in three groups (n ϭ 5 in each group). In group 1, beginning at time 0, 1 ml of isotonic saline (vehicle) was injected icv into the fetus over 5 min. In group 2, Ang I (5 g/kg; Sigma-Aldrich, St. Louis, MO) in 1 ml of isotonic saline was injected icv. In group 3, at Ϫ10 min, a bolus of captopril (1.25 mg/kg; Sigma-Aldrich) was injected icv, and at 0 min, another bolus of captopril (1.25 mg/kg) with Ang I (5 g/kg) was injected. The doses of Ang I and captopril were chosen on the basis of previous reports (33) and our preliminary study. Throughout the study, maternal and fetal systolic and diastolic pressure and heart rate (HR) were monitored continuously. Fetal and maternal systolic (SP) and diastolic pressure (DP) and HR were monitored using a Power Lab Physiological Record with Chart 5 software (AD Instruments).
Endocrine experiments. Throughout the basal and experimental periods, maternal and fetal arterial blood were withdrawn at timed intervals for measurement of pH, blood gases, hematocrit, plasma electrolyte composition, osmolality, and AVP concentrations. Fetal blood samples were replaced with an equivalent volume of heparinized maternal blood withdrawn before the study. Blood PO 2, PCO2, and pH were measured with a Nova analyzer (Model pHOx Plus L; Nova Biochemical, Waltham, MA) adjusted to temperature (39°C). Plasma osmolality was measured by freezing point depression on an Advanced Digimatic osmometer.
Plasma samples were used for AVP radioimmunoassay by using Sep-Pak C18 cartridge extraction. Samples for AVP extraction were acidified with 1 N HCl and extracted. Acidified plasma samples were added slowly to the columns, and the columns were washed with 0.1% trifluoroacetic acid. The absorbed AVP was eluted with 50% methanol and 0.1% trifluoroacetic acid, and the eluates were dried in a SpeedVac concentrator. The assay sensitivity was 1.2 pg for AVP/tube. The intra-and interassay coefficients of variations were 7 and 9%, respectively, for AVP. AVP recovery average was 70% in our laboratory. All plasma samples were processed together.
c-Fos immunoreactivity staining. At the conclusion of the study, the animals were anesthetized and ventilated with a mixture of isoflurane and oxygen, as described. A middle abdominal incision was made, and the fetal head and neck were exposed. A 16-gauge needle was inserted into the fetal carotid artery for perfusion with 0.1 M phosphate-buffered saline followed by 4% paraformaldehyde in 0.1 M phosphate buffer under anesthesia. The perfusion period was ϳ5-7 min, and the fetus was decapitated during perfusion. The brain was removed immediately following perfusion. Postfixation was performed in the paraformaldehyde solution for 12 h, after which the brain was placed in 20% sucrose overnight. Twenty-micrometer coronal sections were cut through the fetal brain on a cryostat. Every other section of the SON and the PVN in the hypothalamus was used for c-fos immunoreactivity (FOS-ir) staining, using the avidin-biotinperoxidase technique. The tissue sections were incubated on a gentle shaker overnight at 4°C in the primary antibody (1:15,000; Santa Cruz Biotechnology, Santa Cruz, CA). The polyclone FOS primary antibody has been raised from rabbits against the NH2-terminal sequence of the FOS protein. The sections were incubated further in a biotinylated goat anti-rabbit serum (1:400) for 1 h and then processed using the Vectastain ABC kit for 1 h (Vector Laboratories, Burlingame, CA) at room temperature. The sections were then treated with 1 mg/ml diaminobenzidine tetrahydrochloride (0.02% hydrogen peroxide; Sigma-Aldrich). All sections were mounted on slides, dehydrated in alcohol, and then coverslipped.
Fos-ir and AVP-ir or AT 1R-ir double labeling. To characterize the positive FOS-ir AVP cells, the hypothalamic sections containing the SON and PVN were first processed using the FOS staining procedure. The presence of bound antibodies was then revealed using fluorescein (Vector Laboratories). The sections were washed with 0.1 M PBS, 5 ϫ 5 min. The selected sections were then incubated in the AVP antibody (1:5,000; Diasorin) or in AT 1R antibody (1:100; Santa Cruz Biotechnology) overnight, after which anti-rabbit antibody-conjugated fluorescein-isothiocyanate (1:200; Vector Laboratories) was applied. All sections were mounted on slides, dehydrated in alcohol, and then coverslipped. The sections were observed with a dark-field microscope with a filter for fluorescein-isothiocyanate excitation for incident light fluorescence.
RT-PCR. We examined the ACE mRNA in the fetal sheep brain (n ϭ 2; GD: 127) by using RT-PCR. The tissue was homogenized, and total RNA was extracted (Biotecx) following phenol-chloroform extraction and ethanol precipitation. The RNA concentration was quantified by an absorbance measurement at 260 nm, and the integrity was assessed by an absorbance measurement at 280 nm. Reverse transcription was achieved using the SuperScript First-Strand Synthesis System (Invitrogen). Amplification of cDNA was performed by usage of the PCR Reagent System (Invitrogen). All primers were constructed with the use of Primer3 software (Invitrogen) and spanned at least two intron sites; thus, genomic DNA contamination would not result in a false signal. Two controls were used in each of the PCR reactions: PCR amplification of sterile water and PCR amplification of DNAase-treated RNA to determine genomic DNA contamination. An ϳ349-bp ACE product was amplified using the following primer pair: sense 5=-CTGCAGTACAAGGACCAGCA-3= and antisense 5=-CGTCAA-AGTGGGTTTCGTTT-3=. The amplification was performed using cycles as follows: 94°C for 5 min followed by 35 cycles (ACE) or 28 cycles (18S) at 94°C for 1 min for denaturation, 60°C for 1 min for annealing, and 72°C for 1 min for elongation, followed by one cycle of 72°C for 7 min for final elongation. Samples were then cooled at 4°C. Cycles were optimized to represent the linear phase of the PCR reaction. The PCR products were electrophoresed on a 1.5% agarose-TAE gel containing 0.5 g/ml ethidium bromide. The mRNA levels of 18S were used as an internal standard to normalize ACE mRNA levels. Water was used for negative control of the experiments, and no ACE signal was found. Visualization of PCR products was achieved using ultraviolet light, and band intensity was measured by scanning densitometry according to the manufacturer's instructions using an IS-1000 Digital Imaging System (version 2.00; Alpha Innotech). As the control, RT-PCRs were performed with and without reverse transcriptase added to the cDNA synthesis reaction.
Analysis. All cardiovascular signals were determined by computer analysis of waveforms using a Power Lab system with Chart 5 software. All stained sections with the interested areas were used for FOS counting, and the mean was taken (n ϭ 5 for each group). The number of FOS-ir positive cells in the SON and PVN was evaluated in a qualitative and blinded manner. The labels on the glass slides were covered during counting, and the data from counting were treated in a blinded manner. We counted positive c-fos staining within the edges of the SON and PVN under Nikon fluorescent microscopy. Counting was from top to bottom and from left to right. The stained hypothalamic sections (multiple sections from each animal) containing the concerned areas in the control and experimental groups (n ϭ 5 each group) were used for counting, and a mean of counted sections was taken. All positive FOS-ir were counted. Colocalization of FOS-ir and AVP-ir in the same sections was also counted. SPSS software was used for statistical analysis. Statistical analysis was performed with repeated-measures ANOVA. Comparisons before and after treatments were determined with one-way ANOVA followed by Tukey post hoc test. P Ͻ 0.05 or 0.01 was the probability level used to define statistical significance. All data were expressed as means Ϯ SE.
RESULTS

RT-PCR.
The prepared RNA generated no product in the PCR controls, which demonstrated no genomic DNA contamination in these RNAs. RT-PCR with ACE-specific sense and antisense primers resulted in the amplification of distinct cDNA fragments of the size of 349 bp. ACE mRNAs were detected in the fetal hypothalamus, olfactory, cerebellum, cortex, and brain stem (Fig. 1) .
Blood values. Intracerebroventricular injection of vehicle, Ang I, or captopril with Ang I had no effect on plasma osmolality, Na ϩ , K ϩ , Cl Ϫ concentrations, arterial blood pH, PO 2 , PCO 2 , hemoglobin, and hematocrit in either maternal or fetal animals (all P Ͼ 0.05; Tables 1 and 2 ). All arterial values were within normal ranges, and there was no significant difference between the control (icv vehicle) and experimental groups (icv Ang I or captopril ϩ Ang I). Cardiovascular responses. Histological analysis confirmed that all cannulae were in the fetal lateral ventricle. Intracerebroventricular injection of Ang I induced significant increases of fetal SP, DP, and mean arterial pressure (MAP) (Fig. 2,  A-C) . The MAP was elevated ϳ25% from baseline (45.2 Ϯ 1.3 mmHg) to a peak (56.2 Ϯ 1.6 mmHg) at 15 min after icv Ang I (P Ͻ 0.01) (Fig. 2C) and maintained for 60 min. In the captopril-treated group, icv injection of captopril alone had no effect on fetal basal SP, DP, and MAP (all P Ͼ 0.05). However, it significantly inhibited Ang I-induced increase of fetal SP, DP, and MAP. The fetal MAP in the captopril-treated group was not significantly different from that of the control group (F 8,1 ϭ 0.14, P Ͼ 0.05). Nevertheless, there was a significant difference in fetal MAP between the animals treated with icv Ang I and icv captopril plus Ang I (F 8,1 ϭ 6.84, P Ͻ 0.05). There was no significant difference between the control and the experimental groups for maternal SP, DP, and MAP (all P Ͼ 0.05). Neither maternal nor fetal HR was changed by icv injection of vehicle, Ang I, or captopril with Ang I into the fetus (Fig. 2D) .
Plasma AVP assay. The fetal AVP concentrations were significantly higher in the group with icv Ang I than that in the control group (F 8,1 ϭ 29.6, P Ͻ 0.01; Fig. 3A ). Intracerebroventricular Ang I significantly increased fetal plasma AVP levels (F 24,5 ϭ 21.3, P Ͻ 0.01, the baseline period vs. the period after icv injection). The peak level of plasma AVP was observed at 15 min following icv injection of Ang I (from baseline level 3.1 Ϯ 1.3 to 30.3 Ϯ 2.7 pg/ml). Then, the increased plasma fetal AVP concentrations gradually decreased. At 60 min following the injection, the fetal plasma AVP was still higher than that of the baseline levels. In the captopril-treated group, icv injection of captopril (2.5 mg/kg) significantly inhibited Ang I-increased fetal plasma AVP. As shown in Fig. 3A , although fetal AVP level at 15 min following icv injection of captopril plus Ang I appeared slightly higher than that of the baseline, there was no significant difference. The fetal plasma AVP levels in the captopril-treated group were not significantly different from those of the control group (AVP; F 8,1 ϭ 0.20, P Ͼ 0.05). Intracerebroventricular injection of vehicle, Ang I, or captopril plus Ang I had no significant effect on maternal plasma AVP levels (all P Ͼ 0.05; Fig. 3B ).
FOS-ir staining.
In the control fetuses following icv vehicle, there was little FOS-ir in the fetal hypothalamic structures, including the PVN and SON. However, icv Ang I produced FOS-ir in the fetal hypothalamus. Intense FOS-ir was observed in the SON and PVN (Figs. 4 and 5) . There was significant difference of FOS-ir in the SON and PVN between the control and Ang I-treated fetuses. Ang I-induced FOS-ir in the PVN was detected in both magnocellular and parvicellular parts. In the captopril-treated group, the number of FOS-ir cells in the SON and PVN was not significantly different from that of the control group.
FOS-ir and AVP-ir double labeling. Double labeling showed that there was no FOS-ir in AVP-containing cells in the brain of control fetuses. However, colocalization of FOS-ir in AVP neurons was detected in both sides of the SON and PVN in the fetal hypothalamus following icv Ang I (Fig. 6) . Although many AVP neurons were colocalized with positive FOS-ir, there were some AVP cells not labeled with FOS-ir. There was no difference in the total counting of AVP-ir in the SON and PVN between the control and the treated fetuses (all P Ͼ 0.05). Double labeling of FOS-ir and AVP-ir in the SON (58.3 Ϯ 5.1%) and PVN (53.5 Ϯ 4.8%) was significantly higher in the Ang I-treated fetuses than that in the control (2.3 Ϯ 0.3 and 1.5 Ϯ 0.2%, respectively) animals (t ϭ 7.2 and 5.8, respectively, P Ͻ 0.01). In addition, double labeling of FOS-ir in the SON and PVN was significantly higher in the Ang I-treated fetuses than that in the captopril-treated (3.2 Ϯ 0.4 and 3.1 Ϯ 0.5%, respectively) animals (t ϭ 8.4 and 11.3, respectively, P Ͻ 0.01).
FOS-ir and AT 1 R-ir double labeling.
As shown in Fig. 7 , intense AT 1 R staining was observed in both the SON and PVN. The positive AT 1 Rs were distributed all over these two nuclei in the fetal brain. There is colocalization of FOS-ir and AT 1 R-ir in both the SON and PVN following icv Ang I. They are significantly higher than the control and captopril-treated groups.
DISCUSSION
The present study demonstrated that icv Ang I could produce Ang II-like pressor responses in the near-term ovine fetus, accompanied by a significant increase of plasma AVP and c-fos expression in the AVP-containing neurons in the fetal SON and PVN. Captopril, a competitive inhibitor of ACE (8), significantly suppressed the increased fetal blood pressure and plasma AVP. Double labeling showed colocalization of AT 1 R and c-fos expression in both SON and PVN following icv Ang I. These results indicate that central endogenous ACE has been functional at least at the last third of gestation in the cardiovascular neural network critical for cardiovascular regulations.
It is well known that there exists local RAS in the brain since most intrinsic components of the central RAS have been demonstrated (23) . As a key enzyme of RAS, ACE's immunoreactivity is present in the human fetal brain (24, 32) , and both ACE mRNA and protein have been detected in the choroid plexus and other brain regions (2, 4, 16, 20) in fetal rats and rabbits. The present study provided new evidence that ACE mRNA can be detected in the sheep fetal brain, including the olfactory region, cortex, hypothalamus, cerebellum, and brain stem, at 90% gestation. A question raised immediately following discovery of ACE in the fetal brain was whether and when the brain ACE in the fetus is functional in physiology. The present study was the first in demonstration that endogenous brain ACE plays an important role in cardiovascular and neuroendocrine functions in utero at late gestation. The finding contributed to the study of neurophysiological effects related to fetal RAS pathways and added new information for both prenatal and postnatal health linked to ACE functions.
In adults, a number of studies support the concept that there are two interacting systems in the brain responsible for Ang II-increased blood pressure: autonomic and hormonal mechanisms. Several hormonal factors, including AVP, may contribute to Ang II-mediated pressor responses, and icv Ang II increases plasma AVP (9) . AVP mechanisms are partially involved in central Ang II-induced pressor responses (11, 13) . A series of studies from our laboratory have demonstrated that icv administration of exogenous Ang II increases fetal arterial pressure and stimulates AVP release at 70 -90% gestation in sheep (35, 36) . In the present study, fetal SP, DP, and MAP were also increased following icv Ang I. This pressor response is similar to that evoked by icv exogenous Ang II, as reported before (35) . Since Ang II is the main biological effector of the RAS, and Ang I needed to be converted to the active peptide to exert physiological or pathophysiological effects, the Ang II-like pressor response following icv Ang I was likely resulting from production of Ang II in the local brain. To confirm this, pharmacological inhibition of the brain ACE was applied. A potent inhibitor of ACE, captopril (8) , prevented the cleavage of the COOH-terminal His-Leu dipeptide from Ang I and blocked the formation of Ang II. The complete blockade of central Ang I-increased fetal SP, DP, and MAP strongly suggests that the effect of fetal brain endogenous ACE had been inhibited. Together, the data demonstrated that the fetal brain ACE is functional in the cardiovascular control at least at near-term in utero. Although such fetal functions appeared quite similar to what we have shown in adults, exact differences or similarities could be distinguished by precise comparisons between adult and fetal models under the exact same conditions.
Considering that enhancement of AVP release is also a critical mechanism to mediate Ang II-induced pressor responses, another important finding in the present study was that fetal plasma AVP levels were increased significantly by icv Ang I. Intracerebroventricular captopril significantly inhibited the Ang I-increased fetal plasma AVP. Therefore, endogenous brain ACE is capable not only in the control of cardiovascular systems but also in regulation of the hypothalamic neuroendocrine network at the last third of gestation.
Accumulating evidence has shown that various signals, including Ang II, hypoxemia, and osmotic and hypovolemic stimulation, can induce AVP production and release from the hypothalamus and pituitary (3, 6, 21, 22, 27, 30, 34) . In the present study, the fetal physiological status remained stable after the surgical recovery period and under the condition of icv Ang I because arterial values were not changed. Notably, unchanged fetal plasma osmolality and sodium levels made it unlikely that the central Ang I-increased fetal AVP was related to osmotic mechanisms. In addition, fetal blood hematocrit and hemoglobin were not affected by the central Ang I, indicating unchanged body fluids and vascular volume. Thus, we can exclude the possibility that hypovolemic or hypotensive factors may contribute to the AVP release. Furthermore, the fetal arterial PO 2 was stable before and after icv Ang I, which made it impossible that the increase of the fetal plasma AVP is linked to hypoxemia following central Ang I administration. In the present study, captopril significantly inhibited the increase of plasma AVP evoked by icv Ang I, providing further evidence that ACE in the fetal brain RAS is functional in the control of endocrine responses.
Several lines of evidence showed that multiple sites in the central nervous system play a role in Ang II-mediated cardiovascular regulation, and those effects by centrally administered Ang II are site specific. In our previous studies, we have demonstrated that Ang II-induced pressor responses in ovine fetuses were associated with neural activation in the critical cardiovascular network, including PVN and SON in the hypothalamus (35, 36) . In the present study, we employed a c-fos mapping technique (5, 17) following icv administrations. This technique has been widely used for indication of neural activation. Intense c-fos was expressed in the SON and PVN following icv Ang I in the fetal brain. Since the SON and PVN are the main source for the plasma AVP (7), activation of a large number of cells in the hypothalamic AVP neurons associated with a significant increase of fetal plasma AVP levels strongly indicated that AVP neurons in these nuclei were activated after icv Ang I in the near-term fetus. Subsequent double immunolabeling experiments showed that many AVPcontaining neurons were activated with c-fos expression. Taken together, icv Ang I-induced fetal plasma AVP increase was linked to the neuronal activation in the hypothalamus, which supports our hypothesis that ACE's physiological functions in the fetal brain RAS have been well developed and established in the neuroendocrine regulation during the last third of gestation.
We have shown that exogenous Ang II-induced cardiovascular and AVP responses may be mediated by AT 1 Rs, since these responses can be blocked by lorsartan (a selective AT 1 R blocker) but not PD123319 (AT 2 receptor selective blocker) (28, 29) , and reported intense AT 1 R immunoreactivity in the fetal PVN and SON (36) with high expression of AT 1 R mRNA and its protein in the fetal hypothalamus by 70% gestation in sheep fetuses (12) . In the present study, immunohistochemistry and double labeling were employed to show the colocalization of AT 1 R and c-fos expression in both SON and PVN following icv Ang I. New evidence was provided for colocalization of AT 1 R and c-fos expression in the hypothalamus following icv Ang I, supporting the hypothesis that Ang II-mediated AVP responses are via AT 1 R located in the PVN and SON of the fetal hypothalamus. In addition, the increased AVP release associated with colocalization of AVP neurons and Fos-ir as well as coexistence of AT 1 R signals and Fos-ir in the SON and PVN strongly suggested that, under the condition of the presence of local endogenous ACE in the fetal brain, icv Ang I increased AVP levels mainly via the AT 1 R pathway in the SON-PVN network in the fetal hypothalamus. In future studies, it is worth investigating extrahypothalamic sites expressed with AT 1 R.
In conclusion, the findings in the present study demonstrate that ACE has been functional in the fetal hypothalamus and other brain areas at late gestation in the control of the cardiovascular and neuroendocrine systems in utero. In light of that, the last third of gestation is critical in functional development and may serve as a vulnerable "window" in the face of environmental insults, leading to disease programming. The novel information gained in the present study contributes not only to understanding of the neurophysiological development in the fetal brain, but also to knowledge of central RASmediated neurophamacological responses in fetal programming.
